Signal Genetics Inc Stock Nasdaq
Equities
US8266401046
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Jun. 11 | Sector Update: Health Care Stocks Mixed Premarket Tuesday | MT |
Jun. 11 | Sector Update: Health Care | MT |
Financials (USD)
Sales 2024 * | 349K | Sales 2025 * | 305K | Capitalization | 886M |
---|---|---|---|---|---|
Net income 2024 * | -230M | Net income 2025 * | -270M | EV / Sales 2024 * | 1,215 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 858 x |
P/E ratio 2024 * |
-3.75
x | P/E ratio 2025 * |
-3.48
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Signal Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 37 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |